NOT ALL ANTIBODIES ARE CREATED EQUAL
Discover the ideal antibodies for therapeutic intent
Creating antibodies with therapeutic potential requires a precision approach to generating, retrieving, and assessing antibodies with the specific properties required for the intended therapeutic effect.
Our Approach
Start Broader: Over 90% of FDA-approved antibodies have their roots in in vivo technologies. At Alloy, we’ve revolutionized this process by introducing our exclusive suite of transgenic humanized mice, featuring an extensive range of human antibody sequence diversity including variety kappa and lambda strains, hyperimmune strains , common light chain strains, and more. We kick off your discovery campaign by capitalizing on this wide diversity, significantly boosting the generation of diverse, high-quality leads tailored to your specific target of interest.
Learn more about our ATX-Gx Transgenic Mouse Platform
Screen Smarter: Comprehensive sequence diversity demands a meticulous screening approach. Alloy has pioneered cutting-edge technologies for mining and sequencing B-cell repertoires. Our arsenal includes a suite of AI/ML tools that systematically scrutinize and pinpoint the most promising candidates. Furthermore, our approach is adaptable, aligning closely with your desired functional characteristics and developability prerequisites.
Drive to the Finish Line
Converting promising hits into viable therapeutic candidates necessitates expertise in protein and format engineering, coupled with preclinical validation assays. At Alloy, we possess the comprehensive skill set and resources to engineer your antibody into a variety of formats and conduct rigorous functional testing, both in vitro and in vivo, using therapeutically relevant models. We provide you with contextual functional validation data, instilling the confidence required to advance your lead assets effectively.
Get in Touch
The Core Antibody Discovery Module offers two advanced screening approaches:
SeqImmune™: This method begins by capturing a broad range of antibodies from the immune repertoire and then narrows down the selection to identify the desired lead. It prioritizes initial diversity of hits and relies on subsequent assays and iterative analysis of the immune repertoire. SeqImmune™ is especially useful when dealing with therapeutic targets lacking initial screening assays or benchmarks, making it suitable for exploratory programs.
DeepImmune™: In contrast, DeepImmune™ takes a functional-first approach by utilizing functional assays right from the start. It emphasizes the early screening of specific functional attributes, like specificity and blocking. This approach is most effective for therapeutic targets with well-understood biology and readily available functionally relevant assays, along with accessible screening reagents.
CORE ANTIBODY DISCOVERY MODULE DELIVERABLE
A robust data package empowering you to proceed with qualified leads
Regardless of which path you choose, our industry-leading antibody biophysical characterization package will give you confidence for lead identification. Analytics packages for both SeqImmune and DeepImmune include:
- Serum titer results
- Binding kinetics and affinity results
- Epitope binning results
- Cell binding assay results
- Cross-reactivity and specificity
- Antibody sequence analysis
POWERFUL ADD-ONS
Five optional service modules accelerate your drug candidate towards the clinic
Expand your core discovery campaign on your teams with a range of modular, add-on services designed to advance your candidate toward the clinic.
BISPECIFICS DISCOVERY
Advanced format engineering leverages our proprietary in vitro platforms and capabilities. We can generate bispecifics building blocks with our semi-synthetic in vitro human VH library for single domain discovery, our naïve or immune common light chain (CLC) phage libraries (Fab) from ATX-Gx repertoires, and our new ATX-CLC™ transgenic mouse.
AFFINITY MATURATION
Robust affinity maturation to drive binding affinities to “therapeutic range”
Leveraging our bioinformatics and in vitro methods, we create and screen phage libraries based on the parental clone to find higher-affinity variants.
ANTIBODY HUMANIZATION
Humanizing antibodies from a variety of species
We deploy bioinformatics and a data-driven approach and can humanize rodent mAbs, rabbit mAbs, camelid VHHs—typically within 12 weeks.
ML-DRIVEN ENGINEERING AND OPTIMIZATION
Iterative in vitro and in silico processes mine and harness immune repertoire diversity
This allows rapid engineering of multiple antibody attributes, and can be accessed as an extension of your core antibody discovery project with us or as a standalone project.
TRANSLATIONAL MEDICINE
Preclinical services support functional validation for lead nomination
Our Translational Medicine team runs in vivo functional screening and in vivo proof of concept to generate functional validation data to give you the confidence to move your lead asset forward.